Annual report
3034.TEDINET S100TXD7
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥161.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥165.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥9.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥101.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥100.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥102.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥53.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥41.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥15.8bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥225m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.55 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.23 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,414.43 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,314.69 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,124.31 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,074.57 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.6% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,856 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,746 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,620 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,517 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,366 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.2bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥6.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥93.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥77.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥67.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥63.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥57.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥30.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥36.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥33.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥179.61 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.76 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,407.23 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,258.81 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥987.71 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 66 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 56 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 49 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 50 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥98m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥478m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥478m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥3.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.0bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | employees | at 2024-03-31 | 4921 pure |
| Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥165.2bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥165.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥89m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2024-03-31 | ¥92.4bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥10.7bn |
| Medical Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥939m |
| Medical Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥151m |
| Medical Related Businessreportable segment | employees | at 2024-03-31 | 819 pure |
| Medical Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥15.3bn |
| Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥15.0bn |
| Medical Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥389m |
| Medical Related Businessreportable segment | segment assets | at 2024-03-31 | ¥11.4bn |
| Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥180.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥180.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥478m |
| —segment total | segment assets | at 2024-03-31 | ¥103.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥11.9bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥170m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥29m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥3.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥76m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2023-03-31 | ¥92.1bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥11.5bn |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥205m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥118m |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥15.0bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥14.7bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥328m |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥11.0bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥8.7bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥170.4bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥170.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥404m |
| —segment total | segment assets | at 2023-03-31 | ¥103.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥13.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,469
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YearDuration | 9000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYearDuration | 0 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1YearDuration | 45000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | CurrentYearDuration | -25000000 | JPY |
| Impairment loss ope cf | Prior1YearDuration | 460000000 | JPY |
| Impairment loss ope cf | CurrentYearDuration | 325000000 | JPY |
| Loss on valuation of inventories ope cf | Prior1YearDuration | － | JPY |
| Loss on valuation of inventories ope cf | CurrentYearDuration | 72000000 | JPY |
| Gain on negative goodwill ope cf | Prior1YearDuration | － | JPY |
| Gain on negative goodwill ope cf | CurrentYearDuration | -25000000 | JPY |
| Gain on sales of investment securities ope cf | Prior1YearDuration | － | JPY |
| Gain on sales of investment securities ope cf | CurrentYearDuration | -2000000 | JPY |
| Surrender value of insurance ope cf | Prior1YearDuration | -229000000 | JPY |
| Surrender value of insurance ope cf | CurrentYearDuration | -514000000 | JPY |
| Interest and dividends income ope cf | Prior1YearDuration | -6000000 | JPY |
| Interest and dividends income ope cf | CurrentYearDuration | -6000000 | JPY |
| Interest expenses ope cf | Prior1YearDuration | 89000000 | JPY |
| Interest expenses ope cf | CurrentYearDuration | 109000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | 703000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | 171000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YearDuration | 1135000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | 448000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | 625000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | 1933000000 | JPY |
| Other net ope cf | Prior1YearDuration | -496000000 | JPY |
| Other net ope cf | CurrentYearDuration | 815000000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 16792000000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 17379000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 6000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 5000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YearDuration | -89000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -109000000 | JPY |
| Income taxes paid ope cf | Prior1YearDuration | -5047000000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -3742000000 | JPY |
| Net cash provided by used in operating activities | Prior1YearDuration | 11662000000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 13533000000 | JPY |
| Payments into time deposits inv cf | Prior1YearDuration | -1000000 | JPY |
| Payments into time deposits inv cf | CurrentYearDuration | -3000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YearDuration | -4168000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -2072000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YearDuration | 16000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 406000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YearDuration | -342000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYearDuration | -242000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 10000000 | JPY |
| Collection of loans receivable inv cf | Prior1YearDuration | 484000000 | JPY |
| Collection of loans receivable inv cf | CurrentYearDuration | 13000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YearDuration | -158000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYearDuration | -219000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |